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ORIGINAL ARTICLE
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ABSTRACT
Introduction: In view of the limited incremental benefit between whole breast irradiation (WBI), accel-
erated partial breast irradiation (APBI) and omission of radiotherapy in favorable early-stage breast can-
cer (ESBC), APBI can only be justified if it combines adequate target coverage with the lowest
achievable toxicity. Interobserver exercises demonstrated the difficulty of precise target delineation,
especially in prone position; information on accuracy is even scarcer. We tested the impact of inserting
an additional indicator clip, marking the depth of the tumor in the breast, and the added value of a
preoperative CT in treatment position on precision and accuracy.
Material and methods: In 12 patients, tumor bed delineation was performed by four radiation oncolo-
gists, with CTVstandard (clinical target volume) based on standard delineation guidelines, CTVclip resulting
from a 1–2-cm symmetrical expansion with the indicator clip as center and CTVclip_CT expanding from
the midpoint between the indicator clip and preoperative gross tumor volume (GTV) as center.
Precision was measured as the mean pairwise Jaccard index (JIpairs) between observers, accuracy as the
mean overlap between GTV and respective CTVs.
Results: JIpairs was 0.38 for CTVstandard, 0.75 for CTVclip and 0.59 for CTVclip_CT. Overlap rate of GTV with
CTVs was respectively 0.48, 0.67 and improved further to 0.88 for CTVclip_CT. High-dose coverage of
GTV (D95 and D90) improved with an indicator clip, but the most optimal result was reached when
preoperative CT was added.
Conclusions: If EB-APBI in prone position is aimed for, an indicator clip intended to mark the depth of
the tumor increases the probability of accurate target coverage, but cannot entirely replace the added
value of a preoperative CT in treatment position. Avoiding the cost and effort of such CT implies a risk
of missing the target, especially when small volumes are aimed for. Increasing target volumes to
reduces this risk, questions the concept of APBI.
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Introduction
Adjuvant radiotherapy is an evidence-based part of breast
conserving therapy, improving local control and overall sur-
vival [1]. These advantages, however, come at the cost of
radiation toxicity as well as burdensome treatment courses.
In answer to these obstacles, accelerated partial breast irradi-
ation (APBI) was introduced for early-stage breast cancer
(ESBC), with acceleration to address the problem of pro-
tracted schedules and reduced target volumes to avoid the
potential consequences of high fraction doses in terms of
esthetic outcome. At the same time, smaller volumes would
facilitate sparing of the surrounding organs at risk (OAR).
Previous trials on adjuvant breast radiotherapy already indi-
cated a relation between irradiated volumes and esthetic
outcome of the breast, and direct proof came recently with
the IMPORT-LOW trial [2–4]. This trial, along with others, also
suggested that APBI is a safe alternative to whole breast
irradiation (WBI) while reducing toxicity [5–8]. However, a
maximum of 5 years’ follow-up may be too short to draw
definitive conclusions, especially in case of favorable ESBC,
where differences in survival only start to emerge afterwards
[1,9]. An even more radical solution to patient burden and
toxicity was tested in the CALGB 9343 and the PRIME trial,
omitting radiotherapy in favorable subgroups [10,11].
Although both trials reported an adverse impact on respect-
ively loco-regional and local control, overall survival was
equivalent. The limited incremental benefit between WBI,
APBI and omission of radiotherapy indicates that APBI can
only be justified if it combines adequate local control, hence
adequate target coverage, with the lowest achiev-
able toxicity.
The IMPORT-LOW trial evaluated hypofractionated
straight-forward tangential-beam field-in-field IMRT for partial
breast irradiation (PBI) as a robust and widely implementable
technique, and results indicated equivalence for tumor con-
trol and overall survival between PBI and WBI [4]. However,
the concept of partial breast is challenged in this trial, as
beam set-up resulted in high-dose delivered to off-target
breast medially and laterally from the tumor bed, including
part of the axilla for targets located in the upper part of
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the breast. Delivering high dose to up to half the breast may
also explain why difference in esthetic outcome was
altogether limited.
In EB-APBI, prone position may help tackling volume and
toxicity issues: it reduces the latero-lateral beam traveling dis-
tance and increases the antero-posterior diameter, both
resulting in reduced high-dose volumes compared to supine
position [12]. These dosimetric advantages however come
at the cost of increased uncertainty in target delineation,
most pronounced in the antero-posterior direction [13].
Interobserver delineation exercises have demonstrated the
difficulties of tumor bed delineation, even in supine position
with seroma present. Clips come at help, but not all clips are
relevant, some are even misleading (Figure 1). Addressing
this uncertainty with larger target volumes would forego the
primary goal of APBI, volume-reduction.
In search of combining precision (high-interobserver con-
formity) with accuracy (high probability of primary tumor
coverage) in prone position and after full thickness closure
(FTC), we tested in an interobserver exercise the impact of
inserting an additional indicator clip, intended for marking
the depth of the tumor in the breast. To test accuracy, the
resulting postoperative clinical target volumes (CTVs) were
compared with the gross tumor volume (GTV) on preopera-
tive CT in treatment position. Tangential-beam APBI using
intensity-modulated radiotherapy (IMRT) was compared with
three-beam IMRT to evaluate the relevance of accuracy and
the dosimetric impact of beam set-up on low- as well as
high-isodose volumes.
Material and methods
Following local Ethics Committee approval of the study, 17
patients with histologically confirmed clinical stage I–II breast
tumors (cT1–2 cN0), candidate for tumorectomy, signed
informed consent and were enrolled between May and
December 2014. Patient, tumor and treatment characteristics
are listed in Table 1. Five patients were excluded after pre-
operative CT because of switch to supine position: in one
patient, multi-centricity necessitated mastectomy and in four
a positive sentinel node was found, requiring lymph node
dissection and irradiation. In the 12 remaining patients, the
tumor was visualized by harpoon in eight patients with non-
palpable tumors and by contrast in four patients with palp-
able tumors.
The preoperative CT scan was performed on a large-bore
Toshiba CT (Aquilion Large Bore, Toshiba), 1 day before
tumorectomy and following the standard image acquisition
protocol (120 kV, 70mA, 3–5mm slices). Patients were
installed in prone position on the breast board. Contrast
enhancement was performed with 100 cc IV Visipaque, GE
Healthcare (2 cc/s, scanning started 100–120 s after start of
injection). Tattoos were applied to help ensuring the same
position on postoperative planning CT.
Surgeons were requested to insert clips according to the
following protocol: incision and localization of the tumor in
the breast with insertion of a 9-mm large titanium ‘indicator
clip’ in the cavity wall at the depth of the ‘resection lump’, to
indicate antero-posterior tumor location as precisely
as possible. Following excision of the tumor, usual ‘cavity
wall’ clips (6mm, titanium), including a deep ‘pectoral fascia’
clip, were placed according to routine practice. FTC was per-
formed in all patients, none underwent oncoplastic surgery.
Four to five weeks after tumorectomy, patients underwent a
planning CT scan in the same position and under the same
conditions as preoperatively, but without contrast.
Delineation was performed by four experienced in-house
radiation oncologists using version 9.8 of the Pinnacle
Figure 1. Illustration of situation with non-informative postoperative clips.
Illustration of a patient with preoperative MRI indicating a tumor location dis-
tant from the thoracic wall. However, on postoperative simulation CT, all clips
were located close to the thoracic wall. For tumor bed delineation (WBI plan
with SIB) none of the clips were enclosed. WBI: whole breast irradiation; SIB:
simultaneously integrated boost.
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Treatment Planning software, Philips Healthcare. For
CTVstandard, volumes were delineated on the planning CT
scan according to existing guidelines, aided by preoperative
information (including surgical and histologic reports and
preoperative imaging but not the preoperative CT in treat-
ment position).
For CTVclip, the indicator clip was located on simulation CT
and symmetrically expanded from the center with a 20-mm
radius [21,22], minus the minimal surgical margin (maximally
10mm). Expansion was limited to the skin, shrunk with
5mm, and excluded the thoracic wall. No other volume cor-
rections were allowed.
The preoperative CT in treatment position was only then
fused with the simulation CT, the primary tumor was
delineated as GTV and a CTVclip_CT was calculated by Gratis,
an in house developed vector-based planning system, as an
automatic expansion from the calculated midpoint between
clip and preoperative GTV.
Mean distance between centers of volumes (dCoV) and
mean of pairwise volume comparisons, using the Jaccard for-
mula (JIpairs), were calculated to evaluate interobserver vari-
ability of CTVs. Pairwise comparison avoids the influence of
the number of observers on the final results [14]. Overlap
coefficient (OC) was calculated as the ratio of the preopera-
tive GTV falling within the CTVs. Distance between indicator
clip and preoperative location of the tumor and between
CTVs and OARs were calculated with Gratis.
Finally, APBI treatment plans were created per delineation
technique, prescribing 28.5 Gy in five fractions to the PTV
(CTV þ5mm, excluding skin minus 5mm and thoracic wall)
with dose fall-off from 28.5 to 20Gy in a surrounding rim of
1 cm. A 2- and a 3-beam set-up with IMRT were applied, with
identical gantry and collimator angle per patient, and couch
rotations for the 3-beam set-up (15 and 340).
Results are reported as means with 95% confidence inter-
vals. The Wilcoxon-signed rank test was used to compare the
delineation techniques, Friedman’s two-way test when more
than two results are compared. Significant difference was
assumed when a confidence level of 95% was reached with
an a-error of 5%.
Results
Results are listed in Tables 2 and 3. Volumes were small, but
symmetric expansion resulted in somewhat higher volumes
for CTVclip compared to standard delineation, due to larger
latero-lateral and cranio-caudal diameters and despite smaller
antero-posterior diameter. Low mean dCoV for CTVclip, indi-
cates good recognizability of the indicator clip. This led to a
high JIpairs for CTVclip compared to CTVstandard (0.75 versus
0.38, p¼ .003). When adaptation of the center was allowed
for CTVclip, JIpairs decreased to 0.59, reflecting a lower agree-
ment on delineation of the GTV, for which a mean dCoV of
7mm was found (1mm if contrast-located versus 10mm if
harpoon-located, p¼ .03).
OC of GTV with CTVs as a proxy for accuracy, was better
for indicator clip-based delineation than for standard delinea-
tion (0.67 versus 0.48, p< .05) and improved even further to
0.88 when information of the preoperative CT was added.
Distance of CTVs to heart and ipsilateral lung was not sig-
nificantly different for both delineation techniques.
Dosimetric characteristics are listed in Table 3. Coverage
of GTV (D95) increased with clip-based delineation, and fur-
ther improved after adding of the preoperative CT. The risk
of relevant underdosing was estimated by the number of
patients with 95% of the GTV receiving <95 and 90% of the
prescribed dose. Standard delineation resulted more often in
severe underdosing or fails then clip-based expansion; the
Table 1. Patient, tumor and treatment characteristics.
Included patients

















Contrast 1 NST 2 10 11 3 No 5 Yes Yes
2 NST 3 27 30 10 Yes 4 Yes Yes
5 Pl_lobul 2 13 14 4 No 5 Yes Yes
8 NST 1 12 8 3 No 3 Yes No
Harpoon 3 Lobular 1 9 5 4 No 5 Yes No
4 NST 2 6 11 4 No 5 Yes Yes
6 NST 3 16 18 0 No 4 No Yes
7 NST 2 7 10 4 No 4 Yes No
9 NST 1 12 8 7 No 1 No Yes
10 NST 1 3 5 3 No 1 No Yes
11 NST 2 8 8 1 No 4 No Yes
12 Lobular 2 12 1 3 No 6 No No
NST: non special type (invasive ductal type); Pl_lobul: peiomorph lobular carcinoma.
Table 2. Comparison of delineation methods following standard guidelines versus a delineation based on an indicator clip only or in combination
with a preoperative CT in treatment position.
Measurements Mean (CI95) GTV CTVstandard CTVclip CTVclip_CT
Volume (cc) 2.1 (0.5–3.7) 17.0 (11.4–22.4) 29.1 (22.0–36.1) 29.0 (22.0–36.1)
Precision CIpairs 0.47 (0.47–0.60) 0.38 (0.32–0.44) 0.75 (0.61–0.89) 0.59 (0.52–0.65)
Accuracy OC (GTV versus CTV) – 0.48 (0.31–0.66) 0.67 (0.43–0.91) 0.88 (0.81–0.96)
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risk increased with 3-beam set-up, as the downside of spar-
ing off-target breast tissue from high dose. Heart and ipsilat-
eral lung dose did not differ significantly (mean heart D2
0.8–1Gy and ipsilateral lung V10 0.2–0.3 Gy).
Discussion
Conformity exercises demonstrate that even in controlled cir-
cumstances, precision of tumor bed delineation in breast
cancer is low: breast tissue is a homogeneous structure with
little reference points for localization. When prone position is
applied, the antero-posterior diameter of the breast increases
and landmarks for delineation change. Tissue distortion is a
radiological sign, indicating high-density regions (glandular
tissue and edema) versus fat tissue. In supine position,
(a)symmetry between left and right breast may to some
extent help to differentiate between edema and glandular
structures, but not in prone position, where compression of
the contralateral breast on the breast board precludes this
comparison. Indirect tumor bed localizers such as clips,
seroma or tissue distortion do not always correlate with pre-
operative imaging. Although they indicate the surgical trajec-
tory, tunneling upon the pectoral fascia may lead to
unnecessarily large irradiated volumes, close to lungs and
heart, thus losing the advantages of prone position and PBI
[15]. The omission of ‘irrelevant clips’ may solve this, however
at the cost of lower interobserver conformity, even if pre-
operative mammography is available [16]. As already sug-
gested by Kirby et al. [17], surgeons plays an important role
and should be informed on the implication of clips on irradi-
ated volumes. Insertion of a minimum of 5–6 clips is recom-
mended, but re-resections may accidently remove such clips.
Kirova et al. [18] found that preoperative CT (supine position)
mainly corrected for left-right discrepancy in tumor bed
delineation. According to Verhoeven et al. [19], this does not
translate into a better Jaccard index. However, with folding
of the breast over the thoracic wall, antero-posterior uncer-
tainty is reduced by natural borders.
Daily practice confirms this target uncertainty. In case of
PBI, geographical miss of the region at risk is not corrected
for by the whole breast component. In view of above-
mentioned results on delineation conformity, and before
starting a trial on EB-APBI in prone position, this feasibility
trial was conceived for evaluating how to improve precision
and accuracy in tumor bed delineation. Recognizability of the
marker was good and resulted in an interobserver conformity
for CTVclip comparable to preoperative exercises [20]. Overlap
rate of GTV with CTVclip compared to CTVstandard improved
with 40%, indicating increased accuracy, even if based on
‘blind’ expansion from this indicator clip only. Fusion of
images with the preoperative CT in treatment position fur-
ther enhanced overlap rates, be it at the cost of interobserver
conformity, which decreased to 0.59. This can be explained
by discrepancy in GTV delineation, especially after harpoon-
localization.
The dosimetric impact of delineation uncertainty was
tested in a planning exercise. When a third beam was added,
high-dose volumes decreased and low-dose volumes
increased. Although GTV coverage, represented as the dose
received by 95% of the volume, did not differ significantly
between delineation strategies or beam set-ups, the GTV D95
receiving <95% and even more pronounced, 90% of the pre-
scribed dose, occurred far more often with standard delinea-
tion. Reducing high-dose volumes by adding a third beam
comes at the cost of a higher probability to miss the target.
More importantly, delineation based on clips, seroma and tis-
sue distortion only may be misleading. It may seem paradox-
ical that underdosing still occurred even after adding the
preoperative CT. However, CTVclip_CT was based on a straight-
forward expansion from the midpoint between clip and pre-
operative GTV. Such a situation is illustrated in Figure 2.
The results invite debate: first, what is the risk of clips
inserted randomly in the cavity walls, potentially marking an
irrelevant part of the surgical trajectory? Introduction of at
least five clips improves delineation precision, but may not
translate into accuracy. A preoperative MRI may correct for
misleading clip location, but is rarely available. Large high-
dose volumes reduce uncertainty, but undermine the con-
cept of APBI.
The most intriguing question is how accurate we need to
be. In ESBC, omission of radiotherapy has little to no impact
on survival [10,11]. The main goal of radiotherapy in this
favorable cohort relies in prevention of relapses, but in favor-
able breast cancer, radiotherapy has only a limited benefit on
local control [1]. Moreover, patients may relapse despite WBI.
Where surgeons’ results are exposed in pathologic reports,
target miss in radiotherapy is obscured by the low recurrence
probabilities of ESBC. Do low relapse rates justify additional
imaging for improving target coverage when APBI is aimed
for, or can we allow a more liberal approach, either by
increasing the volume to compensate for uncertainty or by
accepting the odds of failure? If target coverage is the pri-
mary goal, large volumes will do, but WBI would bring even
more security for an overall small cost in toxicity. If reduction
Table 3. Dosimetric results comparing different delineation methods and beam set-up.
Mean (CI95)
Standard guidelines Clip based Clip and preoperative CT
2 beam 3 beam 2 beam 3 beam 2 beam 3 beam
Breast volume (cc) 787.6 (518.7–1056.5)
Off target breast volume (mean, cc) 603.2 (369.8–836.5) 588.7 (349.8–836.5) 707.6 (419.4–995.7)
GTV D95 (mean, Gy), p¼ NS 24.7 (20.0–29.3) 24.5 (20.4–28.6) 26.1 (23.1–29.2) 25.1 (21.2–29.0) 27.7 (25.9–28.7) 27.7 (27.0–28.4)
GTV D95< 95% dose (no. of patients) 4 5 2 5 2 2
GTV D95< 90% dose (no. of patients) 4 5 2 3 1 1
Breast tissue <20 Gy (mean, %), p< .05 74.4 (70.8–78.0) 77.4 (73.4–81.4) 69.8 (63.9–75.8) 72.6 (66.9–78.3) 71.3 (64.9–77.8) 73.8 (67.0–80.5)
Breast tissue <5 Gy (mean, %), p< .05 61.3 (55.8–66.8) 54.5 (48.3–60.6) 58.7 (50.0–67.3) 54.2 (46.1–62.2) 59.1 (50.5–67.7) 54.3 (45.3–63.8)
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of toxicity and improvement of esthetic outcome are pur-
sued, dedicated preoperative imaging seems needed to avoid
fails in target coverage. The introduction of an indicator clip
may suffice to improve boost delineation, but is in our view
an insufficient compromise for APBI.
A preoperative CT in treatment position does come at a
cost. If APBI is aimed for, introducing this additional step into
the treatment process requires an optimal coordination
between the radiology, surgery and radiotherapy departments.
In only 70% of the patients enrolled in our study the pre-
operative images could be used for target delineation, which
is lower than the 86% of fusible (supine) CT-scans observed by
Boersma et al. [16]. Censoring was in all cases due to upstag-
ing of the disease. Upstaging has also been reported in the
TARGIT trial and ELIOT trial. Preoperative imaging may be
redundant if APBI is replaced by WBI, but not useless, as
upstaging will often require a tumor bed boost.
Some additional cautionary remarks must be made. As
tumor spread is not spherical and can be located eccentric-
ally in the resection specimen. Bartelink et al. [21] have sug-
gested asymmetric application of histopathologic resection
margins for expansion to CTV. However, in view of the
Figure 2. Illustration of dosimetry in a worst-case GTV-coverage. Dosimetry in patient with despite a pT1a tumor (1mm diameter), the worst coverage result of
GTV (black), which is located very medially and more peripherally in the breast than estimated by clips and tissue distortion. Two additional resection specimen had
been excised peroperatively, on CT only one clip was left behind. A CT-slice including the GTV is chosen for illustration. In this patient, CTVstandard and CTVclip did
not overlap with GTV (distance between indicator clip and GTV was 23mm), whereas an overlap ratio of 0.67 was reached for CTVclip_CT. GTV D95 is respectively
17.7, 16.5 and 20.6 Gy for two-beam set-up and 20.0, 11.9 and 24.8 Gy for three-beam set-up.
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disappointing results of a breast specimen orientation exer-
cise by Molina et al. [22], symmetric expansion minus the
minimal margin was estimated a safer option. Asymmetrical
expansion may further reduce CTVclip volumes, but poten-
tially at the cost of accuracy. The impact of an indicator clip
and preoperative imaging was only tested in prone position,
and cannot be translated to supine. The number of patients
was kept low intentionally, as this was only a feasibility trial
exploring the prerequisites for safe EB-APBI. Non-palpable
tumors were located by harpoon instead of contrast, which
in retrospect increased uncertainty. With small tumors being
the primary indication for APBI, combining both techniques
could have brought additional insight in the value of har-
poon-based GTV localization. The study was single-center. All
observers were familiar with tumor bed delineation based on
standard guidelines, not with the new procedure, including
fusion with preoperative CT for GTV delineation. However,
increased experience would probably have further favored
the experimental arm.
In conclusion, if EB-APBI in prone position is aimed for, an
indicator clip clearly intended to mark the depth of the
tumor increases the probability of covering the primary
tumor location, but cannot entirely replace the additional
value of a preoperative CT in treatment position. Avoiding
the cost and effort of such a preoperative CT, implies accept-
ing a risk of missing the target, especially when small vol-
umes are aimed for. Increasing target volumes may reduce
this risk, but questions the concept of APBI. With shorter
treatment schedules and lower costs of EB-APBI compared to
WBI [23], adding a preoperative CT may be considered a mar-
ginal expenditure for improving accuracy.
Acknowledgments
We gratefully acknowledge Ghent University Hospital for the grant
(Klinisch Onderzoeks Fonds) supporting this research. We also acknow-
ledge Annick Van Greveling, study nurse, for motivating breast cancer
patients to participate in this and other ongoing studies. We gratefully
acknowledge Think Pink for funding our study nurse. L.V. holds a Clinical
Mandate of Kom op tegen Kanker.
Funding
This work was financially supported by Ghent University Hospital for the
grant (Klinisch Onderzoeks Fonds) and Think Pink for funding
study nurse.
Disclosure statement
L.O., W.D.G., T.V., T.M., T.V.D.B., H.D. and Y.L. have nothing to disclose.
W.D.N. reports grants from Think pink and from Kom Op Tegen Kanker,




[1] EBCTCG Effect of radiotherapy after breast-conserving surgery on
10-year recurrence and 15-year breast cancer death: meta-analysis
of individual patient data for 10,801 women in 17 randomised tri-
als. Lancet. 2011;378:1707–1716.
[2] Bartelink H, Maingon P, Poortmans P, et al. Whole-breast irradi-
ation with or without a boost for patients treated with breast-
conserving surgery for early breast cancer: 20-year follow-up of a
randomised phase 3 trial. Lancet Oncol. 2015;16:47–56.
[3] Mukesh M, Harris E, Jena R, et al. Relationship between irradiated
breast volume and late normal tissue complications: a systematic
review. Radioth Oncol. 2012;104:1–10.
[4] Coles CE, Griffin CL, Kirby AM, et al. Partial-breast radiotherapy
after breast conservation surgery for patients with early breast
cancer (UK IMPORT LOW trial): 5-year results from a multicentre,
randomised, controlled, phase 3, non-inferiority trial. Lancet.
2017;390:1048–1060.
[5] Veronesi U, Orecchia R, Maisonneuve P, et al. Intraoperative radio-
therapy versus external radiotherapy for early breast cancer
(ELIOT): a randomised controlled equivalence trial. Lancet Oncol.
2013;14:1269–1277.
[6] Vaidya JS, Wenz F, Bulsara M, et al. Risk-adapted targeted
intraoperative radiotherapy versus whole-breast radiotherapy
for breast cancer: 5-year results for local control and overall sur-
vival from the TARGIT-a randomised trial. Lancet. 2014;383:
603–613.
[7] Livi L, Meattini I, Marrazzo L, et al. Accelerated partial breast
irradiation using intensity-modulated radiotherapy versus whole
breast irradiation: 5-year survival analysis of a phase 3 rando-
mised controlled trial. Eur J Cancer. 2015;51:451–463.
[8] Strnad V, Ott OJ, Hildebrandt G, et al. Five-year results of acceler-
ated partial breast irradiation using sole interstitial multicatheter
brachytherapy versus whole-breast irradiation with boost after
breast-conserving surgery for low-risk invasive and in-situ carcin-
oma of the female breast: a randomised, phase 3, non-inferiority
trial. Lancet. 2016;387(10015):229–238.
[9] Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of
differences in the extent of surgery for early breast cancer on
local recurrence and 15-year survival: an overview of the rando-
mised trials. Lancet. 2005;366:2087–2106.
[10] Kunkler IH, Williams LJ, Jack WJ, et al. Breast-conserving surgery
with or without irradiation in women aged 65 years or older with
early breast cancer (PRIME II): a randomised controlled trial.
Lancet Oncol. 2015;16:266–273.
[11] Hughes KS, Schnaper LA, Bellon JR, et al. Lumpectomy plus tam-
oxifen with or without irradiation in women age 70 years or older
with early breast cancer: long-term follow-up of CALGB 9343.
J Clin Oncol. 2013;31:2382–2387.
[12] Mulliez T, Speleers B, Madani I, et al. Whole breast radiotherapy
in prone and supine position: is there a place for multi-beam
IMRT? Radiat Oncol. 2013;8:151.
[13] Mulliez T, Veldeman L, van Greveling A, et al. Hypofractionated
whole breast irradiation for patients with large breasts: a random-
ized trial comparing prone and supine positions. Radioth Oncol.
2013;108:203–208.
[14] Kouwenhoven E, Giezen M, Struikmans H. Measuring the similarity
of target volume delineations independent of the number of
observers. Phys Med Biol. 2009;54:2863–2873.
[15] Lakosi F, Gulyban A, Simoni SB, et al. The influence of treatment
position (prone vs. supine) on clip displacement, seroma, tumor
bed and partial breast target volumes: comparative study. Pathol
Oncol Res. 2016;22:493–500.
[16] Boersma LJ, Janssen T, Elkhuizen PH, et al. Reducing interobserver
variation of boost-CTV delineation in breast conserving radiation
therapy using a pre-operative CT and delineation guidelines.
Radioth Oncol. 2012;103:178–182.
[17] Kirby AM, Jena R, Harris EJ, et al. Tumour bed delineation for par-
tial breast/breast boost radiotherapy: what is the optimal number
of implanted markers? Radioth Oncol. 2013;106:231–235.
[18] Kirova YM, Fournier-Bidoz N, Servois V, et al. How to boost the
breast tumor bed? A multidisciplinary approach in eight steps. Int
J Radiat Oncol Biol Phys. 2008;72:494–500.
6 C. MONTEN ET AL.
[19] Verhoeven K, Peeters S, Erven K, et al. Is the use of a preoperative
computed tomography beneficial to reduce the interobserver
variability of the CTVboost delineation for breast radiation ther-
apy? Pract Radiat Oncol. 2016;6:376.
[20] van der Leij F, Elkhuizen PH, Janssen TM, et al. Target volume
delineation in external beam partial breast irradiation: less inter-
observer variation with preoperative- compared to postoperative
delineation. Radioth Oncol. 2014;110:467–470.
[21] Bartelink H, Bourgier C, Elkhuizen P. Has partial breast irradiation
by IORT or brachytherapy been prematurely introduced into the
clinic? Radiother Oncol. 2012;104:139–142.
[22] Molina MA, Snell S, Franceschi D, et al. Breast specimen orienta-
tion. Ann Surg Oncol. 2009;16:285–288.
[23] Monten C, Lievens Y. Adjuvant breast radiotherapy: how to
trade-off cost and effectiveness? Radiother Oncol. 2018;126:
132–138.
ACTA ONCOLOGICA 7
